Second lumpectomy for breast cancer reduces survival ratesOctober 03, 2008UC Davis researchers find disturbing trend in treating recurrent breast cancer (SACRAMENTO, Calif.) - A majority of women with breast cancer today are candidates for lumpectomy, allowing for conservation of most of their breast tissue. Results of a UC Davis study, however, show that a number of women whose cancer recurs in the same breast are treated with a second lumpectomy rather than a mastectomy, defying current treatment recommendations and cutting the number of years those women survive in half. "We were surprised to find that so many women in our study - almost a quarter of them - had received another lumpectomy rather than a mastectomy," said Steven Chen, a UC Davis Cancer Center surgical oncologist and lead author of the study, which appears in the October issue of the American Journal of Surgery. "It's likely that patients are asking for lumpectomies when their cancer is diagnosed a second time, and their doctors are simply complying with that request. Whatever the reason, that decision can shorten life spans."
Chen and study co-author, Steve Martinez, also a UC Davis Cancer Center surgical oncologist, gathered data from the National Cancer Institute's Surveillance, Epidemiology and End Results database, which includes information on all cancers diagnosed in selected regions throughout the nation. Their study included 747 patients who previously received breast-conservation therapy and were diagnosed with cancer a second time in the same breast between 1988 and 2004. The authors found that women who had mastectomies had a 78 percent survival rate after five years, while those who had second lumpectomies had a 67 percent survival rate. The 10-year survival rates were 62 percent for those who had mastectomies and 57 percent for those who had second lumpectomies. In all, 24 percent of women with recurrent breast cancer in the same breast had second lumpectomies. The researchers went on to calculate the risk of dying for mastectomy patients compared to lumpectomy patients. They found that, after adjusting for factors that affect survival, there will be half as many survivors at any given time in the lumpectomy group versus the mastectomy group. Chen explained that a mastectomy is the generally accepted surgical treatment for a second cancer because whole breast radiation, which typically accompanies a lumpectomy, is not usually recommended twice in a lifetime. This new study shows as well that there is a survival advantage to those who choose a mastectomy. According to Martinez, knowledge of breast cancer and its treatments are continuously advancing, and second lumpectomies could at some point become a viable option. "As therapy for breast cancer becomes more targeted and researchers come closer to identifying those factors that make some breast cancers more aggressive than others, we may have the option of recommending second and even third lumpectomies in select cases in the future. Until then, mastectomy remains the best option for women experiencing a same-breast recurrence of their breast cancer," he said. University of California - Davis - Health System | |||||||||||||||||||||
|
Related Breast Cancer Current Events and Breast Cancer News Articles Hormone therapy associated with reduced colorectal cancer risk The combination of estrogen plus progestin, which women stopped taking in droves following the news that it may increase their risk of breast cancer, may decrease their risk of colorectal cancer, according to a report published in the January issue of Cancer Epidemiology, Biomarkers and Prevention, a journal of the American Association for Cancer Research. Team finds breast cancer gene linked to disease spread A team of researchers at Princeton University and The Cancer Institute of New Jersey has identified a long-sought gene that is fatefully switched on in 30 to 40 percent of all breast cancer patients, spreading the disease, resisting traditional chemotherapies and eventually leading to death. Dormant cancer cells rely on cellular self-cannibalization to survive A single tumor-suppressing gene is a key to understanding, and perhaps killing, dormant ovarian cancer cells that persist after initial treatment only to reawaken years later, researchers at The University of Texas M. D. Anderson Cancer Center report in the December Journal of Clinical Investigation. How to enhance non-thermal effects of ultrasound In recent years HIFU has been widely used for the treatment of solid tumors, such as liver tumor, bone tumor, and breast cancer. The mechanism for therapeutic actions of HIFU includes thermal effects and non-thermal effects with the latter dominated by cavitational effects. Obesity Increases Lymphedema Risk for Breast Cancer Survivors Throughout the world, 10 million breast cancer survivors have a lifetime risk for developing lymphedema, a chronic condition that involves swelling of the limbs and impacts physical and psychosocial health. Researchers compile 'molecular manual' for 100s of inherited diseases An international research team has compiled the first catalogue of tissue-specific pathologies underlying hundreds of inherited diseases. Modified gene targets cancer cells a thousand times more often than healthy cells Researchers at the University of Rochester have designed a gene that produces a thousand times more protein in cancer cells than in healthy cells. Meta-analyses of global trials finds in favor of aromatase inhibitors Two separate meta-analyses of clinical trials from around the world that tested tamoxifen against aromatase inhibitor drugs in postmenopausal women with early breast cancer have each reached the same conclusion: aromatase inhibitors are more effective in preventing breast cancer from coming back. Interactive gene 'networks' may predict if leukemia is aggressive or slow-growing Rather than testing for individual marker genes or proteins, researchers at the University of California, San Diego (UC San Diego) and the Moores UCSD Cancer Center have evidence that groups, or networks, of interactive genes may be more reliable in determining the likelihood that a form of leukemia is fast-moving or slow-growing. Confusing risk information may lead to poor cancer treatment choices A new study from researchers at the University of Michigan Comprehensive Cancer Center found that a tool commonly used by doctors to estimate the risk of a woman's breast cancer returning after surgery is not very effective at explaining risk to patients. More Breast Cancer Current Events and Breast Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||